Abstract
Friedreich ataxia (FA) is an autosomal-recessive disease primarily characterized by progressive neurological disability. A significant proportion of patients also present with a hypertrophic cardiomyopathy, which may, in some cases, cause premature death. FA is caused by insufficient levels of the protein, frataxin, which is involved in mitochondrial iron metabolism. All patients carry at least one copy of an intronic GAA triplet-repeat expansion that interferes with frataxin transcription. Normal chromosomes contain up to 35 to 40 GAA triplets in an Alu sequence localized in the first intron of the frataxin gene; FA chromosomes carry from approx 70 to more than 1000 GAA triplets. The molecular diagnosis of FA is, therefore, based on the detection of this expansion, which is present in homozygosity in more than 95% of the cases. The remaining patients are heterozygous for the GAA expansion and carry a frataxin point mutation as the other pathogenic allele. The expanded GAA triplet repeat may be detected by polymerase chain reaction (PCR) amplification followed by agarose gel electrophoresis analysis. In our hands, carefully performed PCR testing, in particular, if fragment detection is enhanced by hybridization with a GAA oligonucleotide probe, is as effective in identifying patients and carriers as is Southern blot analysis of genomic DNA, and allows a more accurate sizing of the repeat. Furthermore, in the case of smaller expansions, the amplified fragment may be directly sequenced to identify very rare nonpathogenic variant repeats, such as GAAGGA. Sequence analysis of the five coding exons of the frataxin gene should be performed in clinically affected individuals who are heterozygous for an expanded GAA repeat to identify point mutations.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Geoffroy, G., Barbeau, A., Breton, G., et al. (1976) Clinical description and roentgenologic evaluation of patients with Friedreich ataxia. Can. J. Neurol. Sci. 3, 279–286.
Harding, A. E. (1981) Friedreich ataxia: a clinical and genetic study of 90 families with an analysis of early diagnosis criteria and intrafamilial clustering of clinical features. Brain 104, 589–620.
Filla, A. De Michele, G., Caruso, G., Marconi, R., and Campanella, G. (1990) Genetic data and natural history of Friedreich disease: a study of 80 Italian patients. J. Neurol. 237, 345–351.
Muller-Felber, W., Rossmanith, T., Spes, C., Chamberlain, S., Pongratz, D., and Deufel, T. (1993) The clinical spectrum of Friedreich ataxia in German families showing linkage to the FRDA locus on chromosome 9. Clin. Investig. 71, 109–114.
Campanella, G., Filla, A. De Falco, F. Mansi, D., Durivage, A., and Barbeau, A.(1980) Friedreich ataxia in the south of Italy: A clinical and biochemical survey of 23 patients. Can. J. Neurol. Sci. 7, 351–357.
D’Angelo, A., Di Donato, S., Negri, G., Beulche, F., Uziel, G. and Boeri, R. (1980) Friedreich ataxia in northern Italy: I. Clinical, neurophysiological and in vivo biochemical studies. Can. J. Neurol. Sci. 7, 359–365.
Ulku, A., Arac, N., and Ozeren, A. (1988) Friedreich ataxia: a clinical review of 20 childhood cases. Acta Neurol. Scand. 77, 493–497.
De Michele, G., Di Maio, L., Filla, A., et al. (1996) Childhood onset of Friedreich ataxia: a clinical and genetic study of 36 cases. Neuropediatrics 27, 3–7
Klockgether, T., Chamberlain, S., Wullner, U., et al. (1993) Late-onset Friedreich ataxia. Molecular genetics, clinical neurophysiology, and magnetic resonance imaging. Arch. Neurol. 50, 803–806.
De Michele, G., Filla, A., Cavalcanti, F., et al. (1994) Late onset Friedreich disease: clinical features and mapping of mutation to the FRDA locus. J. Neurol. Neurosurg. Psychiatry 57, 977–979.
Gentil, M. (1990) Dysarthria in Friedreich disease. Brain Lang. 38, 438–448.
Cisneros, E. and Braun, C. M. (1995) Vocal and respiratory diadochokinesia in Friedreich ataxia. Neuropathological correlations. Rev. Neurol. (Paris) 151, 113–123.
Beauchamp, M., Labelle, H., Duhaime, M., and Joncas, J. (1995) Natural history of muscle weakness in Friedreich’s Ataxia and its relation to loss of ambulation. Clin Orthop. 311, 270–275.
Spieker, S., Schulz, J. B., Petersen, D., Fetter, M., Klockgether, T., and Dichgans, J. (1995) Fixation instability and oculomotor abnormalities in Friedreich ataxia. J. Neurol. 242, 517–521.
Kirkham, T. H. and Coupland, S. G. (1981) An electroretinal and visual evoked potential study in Friedreich ataxia. Can. J. Neurol. Sci. 8, 289–294.
Livingstone, I. R., Mastaglia, F. L., Edis, R., and Howe, J. W. (1981) Visual involvement in Friedreich ataxia and hereditary spastic ataxia. A clinical and visual evoked response study. Arch. Neurol. 38, 75–79.
Rabiah, P. K., Bateman, J. B., Demer, J. L., and Perlman, S. (1997) Ophthalmologic findings in patients with ataxia. Am. J. Ophthalmol. 123, 108–117.
Ell, J., Prasher, D., and Rudge, P. (1984) Neuro-otological abnormalities in Friedreich ataxia. J. Neurol. Neurosurg. Psychiatry 47, 26–32.
Cassandro, E., Mosca, F., Sequino, L., De Falco, F. A., and Campanella, G. (1986) Otoneurological findings in Friedreich ataxia and other inherited neuropathies. Audiol. 25, 84–91.
Montermini, L., Richter, A., Morgan, K., et al. (1997) Phenotypic variability in Friedreich ataxia: role of the associated GAA triplet repeat expansion. Ann. Neurol. 41, 675–682.
Leone, M., Rocca, W. A., Rosso, M.G., Mantel, N., Schoenberg, B. S., and Schiffer, D. (1988) Friedreich disease: survival analysis in an Italian population. Neurology 38, 1433–1438.
Hartman, J. M. and Booth, R. W. (1960) Friedreich ataxia: a neurocardiac disease. Am. Heart J. 60, 716–720.
Boyer, S. H., Chisholm, A. W., and McKusick, V. A. (1962) Cardiac aspects of Friedreich ataxia. Circulation 25, 493–505.
Harding, A. E. and Hewer, R. L. (1983) The heart disease of Friedreich ataxia. A clinical and electrocardiographic changes in 30 cases. Q. J. Med. 52, 489–502.
Pentland, B. and Fox, K. A. (1983) The heart in Friedreich ataxia. J. Neurol. Neurosurg. Psychiatry 46, 1138–1142.
Child, J. S., Perloff, J. K., Bach, P. M., Wolfe, A. D., Perlman, S., and Kark, R. A.(1986) Cardiac involvement in Friedreich ataxia: a clinical study of 75 patients. J. Am. Coll. Cardiol. 7, 1370–1378.
Alboliras, E. T., Shub, C., Gomez, M. R., et al. (1986) Spectrum of cardiac involvement in Friedreich ataxia: clinical, electrocardiographic and echocardiographic observations. Am. J. Cardiol. 58, 518–524.
Maione, S., Giunta, A., Filla, A., et al. (1997) May age onset be relevant in the occurrence of left ventricular hypertrophy in Friedreich ataxia? Clin. Cardiol. 20, 141–145.
Finocchiaro, G., Baio, G., Micossi, P., Pozza, G., and Di Donato, S. (1988) Glucose metabolism alterations in Friedreich ataxia. Neurology 38, 1292–1296.
Schoenle, E. J., Boltshauser, E. J., Baekkeskov, S., Landin Olsson, M., Torresani, T., and von Felten, A.(1989) Preclinical and manifest diabetes mellitus in young patients with Friedreich ataxia: no evidence of immune process behind the islet cell destruction. Diabetologia 32, 378–381.
Fantus, I. G., Seni, M. H., and Andermann, E. (1993) Evidence for abnormal regulation of insulin receptors in Friedreich ataxia. J. Clin. Endocrinol. Metab. 76,60–63.
Margalith, D., Dunn, H. G., Carter, J. E., and Wright, J. M. (1984) Friedreich ataxia with dysautonomia and labile hypertension. Can. J. Neurol. Sci. 11, 73–77.
Pousset, F., Kalotka, H., Durr, A., et al. (1996) Parasympathetic activity in Friedrich’s ataxia. Am. J. Cardiol. 78, 847–850.
McLeod, J. G. (1971) An electrophysiological and pathological study of peripheralnerves in Friedreich ataxia. J. Neurol. Sci. 12, 333–349.
Peyronnard, J. M., Bouchard, J. P., and Lapointe, M. (1976) Nerve conduction studies and electromyography in Friedreich ataxia. Can. J. Neurol. Sci. 3, 313–317.
Ackroyd, R.S., Finnegan, J.A., and Green, S.H. (1984) Friedreich ataxia. A clinical review with neurophysiological and echocardiographic findings. Arch. Dis. Child. 59, 217–221.
Wullner, U., Klockgether, T., Petersen, D., Naegele, T., and Dichgans, J. (1993) Magnetic resonance imaging in hereditary and idiopathic ataxia [see comments]. Neurology 43, 318–325.
Morvan, D., Komajda, M., Doan, L. D., et al. (1992) Cardiomyopathy in Friedreich ataxia: a Doppler-echocardiographic study. Eur. Heart J. 13, 1393–1398.
Chamberlain, S., Shaw, J., and Rowland, A. (1998) Mapping of mutation causing Friedreich’s ataxia to human chromosome 9. Nature 334, 248–250.
Campuzano, V., Montermini, L., Moltö, M. D., et al. (1996) Friedreich ataxia:autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271, 1423–1427.
Koutnikova, H., Campuzano, V., Foury, F., Dollé, P., Cazzalini, O., and Koenig, M. (1997) Studies of human, mouse and yeast homologues indicate a mitochondrial function for frataxin. Nat. Genet. 16, 345–351.
Jiralerspong, S., Liu, Y., Montermini, L., Stifani, S., and Pandolfo, M. (1997) Frataxin shows developmentally regulated tissue-specific expression in the mouse embryo. Neurobiol. Dis. 4, 103–113.
Campuzano, V., Montermini, L., Lutz, Y., et al. (1997) Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum.Mol. Genet. 6, 1771–1780.
Dürr, A. Cossée, M., Agid, Y., et al. (1996) Clinical and genetic abnormalities in patients with Friedreich ataxia. N. Engl. J. Med. 335, 1169–1175.
Ohshima, K., Montermini, L., Wells, R. D., and Pandolfo, M. (1998) Inhibitory effects of expanded GAA•TTC triplet repeats from intron I of the Friedreich ataxia gene on transcription and replication in vivo. J. Biol. Chem. 273, 14,588–15,595.
Sakamoto, N. K., Ohshima, K. L., Montermini, L. M., Pandolfo, M., and Wells, R. D. (2001) Sticky DNA, a self-associated complex formed at long GAA•TTC repeats in intron 1 of the Frataxin gene, inhibits transcription. J. Biol. Chem. 276,27,171–27,177.
Sakamoto, N., Chastain, P. D., Parniewski, P., et al. (1999) Sticky DNA: selfassociation properties of long GAA•TTC repeats in R•R•Y triplex structures fromFriedreich ataxia. Mol. Cell 3, 465–475.
Cossée, M., Dürr, A., Schmitt, M., et al. (1999) Frataxin point mutations and clinicalpresentation of compound heterozygous Friedreich ataxia patients. Ann.Neurol. 45, 200–206.
Dhe-Paganon, S., Shigeta, R., Chi, Y. I., Ristow, M., and Shoelson, S. E. (2000) Crystal structure of human frataxin. J. Biol. Chem. 275, 30,753–30,756.
Musco, G., Stier, G., Kolmerer, B., et al. (2000) Towards a structural understanding of Friedreich ataxia: the solution structure of frataxin. Structure Fold. Des. 8,695–707.
Cho, S. J., Lee, M. G., Yang, J. K., Lee, J. Y., Song, H. K., and Suh, S. W. (2000) Crystal structure of Escherichia coli CyaY protein reveals a previously unidentified fold for the evolutionarily conserved frataxin family. Proc. Natl. Acad. Sci USA 97, 8932–8937.
Babcock, M., de Silva, D., Oaks, R., et al. (1997) Regulation of mitochondrial iron accumulation by Yfh1, a putative homolog of frataxin. Science 276, 1709–1712.
Wilson, R. B. and Roof, D. M. (1997) Respiratory deficiency due to loss of mitochondrial DNA in yeast lacking the frataxin homologue. Nat. Genet. 16, 352–357.
Radisky, D. C., Babcock, M. C., and Kaplan, J. (1999) The yeast frataxin homologue mediates mitochondrial iron efflux. Evidence for a mitochondrial iron cycle. J. Biol. Chem. 274, 4497–4499.
Rötig, A., deLonlay, P., Chretien, D., et al. (1997) Frataxin gene expansion causes aconitase and mitochondrial iron-sulfur protein deficiency in Friedreich ataxia. Nat. Genet. 17, 215–217.
Gardner, P. R., Rainieri, I., Epstein, L. B., and White, C. W. (1995) Superoxide radical and iron modulate aconitase activity in mammalian cells. J. Biol. Chem. 270, 13,399–13,405.
Muhlenhoff, U., Gerber, J., Richhardt, N., and Lill, R. (2003) Components involved in assembly and dislocation of iron-sulfur clusters on the scaffold protein Isu1p. EMBO J. 22, 4815–4825.
Yoon, T. and Cowan, J. A. (2003) Iron-sulfur cluster biosynthesis. Characterization of frataxin as an iron donor for assembly of [2Fe-2S] clusters in ISU-type proteins. J. Am. Chem. Soc. 125, 6078–6084.
Yoon, T. and Cowan, J. A. (2004) Frataxin-mediated iron delivery to ferrochelatase in the final step of heme biosynthesis. J. Biol. Chem. 279, 25,943–25,946.
Bulteau, A. L., O’Neill, H. A., Kennedy, M. C., Ikeda-Saito, M., Isaya, G., and Szweda, L. I. (2004) Frataxin acts as an iron chaperone protein to modulate mitochondrial aconitase activity. Science 305, 242–245.
Pandolfo, M. (2002) Iron metabolism and mitochondrial abnormalities in Friedreich ataxia. Bl. Cells Mol. Dis. 29, 536–547.
Adamec, J., Rusnak, F., Owen, W. G., et al. (2000) Iron-dependent self-assembly of recombinant yeast frataxin: implications for Friedreich ataxia. Am. J. Hum. Genet. 67, 549–562.
Park, S., Gakh, O., O’Neill, H. A., et al. (2003) Yeast frataxin sequentially chaper-ones and stores iron by coupling protein assembly with iron oxidation. J. Biol. Chem. 278, 31,340–31,345.
Lamarche, J. B., Côté, M., and Lemieux, B. (1980) The cardiomyopathy of Friedreich ataxia morphological observations in 3 cases. Can. J. Neurol. Sci. 7, 389–396.
Emond, M., Lepage, G., Vanasse, M., and Pandolfo, M. (2000) Increased levels of plasma malondialdehyde in Friedreich ataxia. Neurology 55, 1752–1753.
Schulz, J. B., Dehmer, T., Schols, L., et al. (2000) Oxidative stress in patients with Friedreich ataxia. Neurology 55, 1719–1721.
Santos, M., Ohshima, K., and Pandolfo, M. (2001) Frataxin deficiency enhances apoptosis in cells differentiating into neuroectoderm. Hum. Mol. Genet. 10, 1935–1944.
Wong, A., Yang, J., Cavadini, P., et al. (1999) The Friedreich ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis. Hum. Mol. Genet. 8, 425–430.
Jiralerspong, S., Ge, B., Hudson, T. J., and Pandolfo, M. (2001) Manganese super-oxide dismutase induction by iron is impaired in Friedreich ataxia cells. FEBS Lett. 509, 101–105.
Lodi, R., Cooper, J. M., Bradley, J. L., et al. (1999) Deficit of in vivo mitochon-drial ATP production in patients with Friedreich ataxia. Proc. Natl. Acad. Sci.USA 96, 11,492–11,495.
Cossée, M., Puccio, H., Gansmuller, A., et al. (2000) Inactivation of the Friedreich ataxia mouse gene leads to early embryonic lethality without iron accumulation. Hum. Mol. Genet. 9, 1219–1226.
Puccio, H., Simon, D., Cossee, M., et al. (2001) Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency fol-lowed by intramitochondrial iron deposits. Nat. Genet. 27, 181–186.
Miranda, C. J., Santos, M. M., Ohshima, K., et al. (2002) Frataxin knockin mouse. FEBS Lett. 512, 291–297.
Simon, D., Seznec, H., and Gansmuller, A. (2004) Friedreich ataxia mouse models with progressive cerebellar and sensory ataxia reveal autophagic neurodegeneration in dorsal root ganglia. J. Neurosci. 24, 1987–1995.
Schols, L., Vorgerd, M., Schillings, M., Skipka, G., and Zange, J. (2001) Idebenone in patients with Friedreich ataxia. Neurosci. Lett. 306(3), 169–172.
Hausse, A. O., Aggoun, Y., Bonnet, D., et al. (2002) Idebenone and reduced cardiac hypertrophy in Friedreich’s ataxia. Heart 87(4), 346–349.
Mariotti, C., Solari, A., Torta, D., Marano, L., Fiorentini, C., and Di Donato, S.(2003) Idebenone treatment in Friedreich patients: one-year-long randomized pla-cebo-controlled trial. Neurol. 60(10), 1676–1679.
Buyse, G., Mertens, L., Di Salvo, G., et al. (2003) Idebenone treatment in Friedreich’s ataxia: neurological, cardiac, and biochemical monitoring. Neurol. 60(10), 1679–1681.
Seznec, H., Simon, D., Monassier, L., et al. (2004) Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia. Hum. Mol. Genet. 13(10), 1017–1024.
Lodi, R., Hart, P. E., Rajagopalan, B., et al. (2001) Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich’s ataxia. Ann. Neurol. 49, 590–596.
Schols, L., Vorgerd, M., Schillings, M., Skipka, G., and Zange, J. (2001) Idebenone in patients with Friedreich ataxia. Neurosci. Lett. 306, 169–172.
Hausse, A.O., Aggoun, Y., Bonnet, D., et al. (2002) Idebenone and reduced cardiac hypertrophy in Friedreich’s ataxia. Heart 87, 346–349.
Mariotti, C., Solari, A., Torta, D., Marano, L., Fiorentini, C., and Di Donato, S.(2003) Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurol. 60, 1676–1679.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Humana Press Inc.
About this protocol
Cite this protocol
Pandolfo, M. (2006). Friedreich Ataxia. In: Kearns-Jonker, M. (eds) Congenital Heart Disease. Methods in Molecular Medicine, vol 126. Humana Press. https://doi.org/10.1385/1-59745-088-X:197
Download citation
DOI: https://doi.org/10.1385/1-59745-088-X:197
Publisher Name: Humana Press
Print ISBN: 978-1-58829-375-6
Online ISBN: 978-1-59745-088-1
eBook Packages: Springer Protocols